Target Information

Target General Infomation
Target ID
T63068
Former ID
TTDS00336
Target Name
Serum albumin
Gene Name
ALB
Synonyms
ALB
Target Type
Successful
Disease Arthritis; Bursitis [ICD10: M00-M25]
Cholecystography; Gallbladder disease [ICD9:574, 575; ICD10: K81, K82, K80-K82]
Constipation [ICD9: 564; ICD10: K59.0]
Diarrhea [ICD9: 787.91; ICD10: A09, K59.1]
Hemophilia [ICD9: 286; ICD10: D66-D68]
Hypovolemic shock; hypoalbuminemia [ICD10: E88.09]
Imaging [ICD10: W88]
Reperfusion injury and stroke [ICD9: 410, 434.91; ICD10: I21, I22, I61-I63]
Visualizing lesions with abnormal blood brain barrier [ICD9: 437.9; ICD10: I67.9]
Xerophthalmia [ICD10: E50.6-E50.7]
Function
Serum albumin, the main protein of plasma,has a good binding capacity for water, ca(2+), na(+), k(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood.
BioChemical Class
Serum albumin family
Target Validation
T63068
UniProt ID
P02768
Sequence
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL
Drugs and Mode of Action
Drug(s) Albumin Human Drug Info Approved Hypovolemic shock; hypoalbuminemia [1]
Bismuth Drug Info Approved Diarrhea [2]
Ebselen Drug Info Approved Reperfusion injury and stroke [3]
EVANS BLUE Drug Info Approved Blood volume and Cardiac output measurement [4]
Gadobenate Dimeglumine Drug Info Approved Visualizing lesions with abnormal blood brain barrier [5], [6], [1]
Gadofosveset Drug Info Approved Imaging [7]
Iodipamide Drug Info Approved Cholecystography; Gallbladder disease [8], [9], [1]
Oxyphenbutazone Drug Info Approved Arthritis; Bursitis [1]
Sodium lauryl sulfate Drug Info Approved Constipation [10]
Activated recombinant FVII-albumin fusion protein Drug Info Phase 2/3 Hemophilia [11]
RU-101 Drug Info Phase 1/2 Xerophthalmia [12]
Modulator Activated recombinant FVII-albumin fusion protein Drug Info [13]
Albumin Human Drug Info [14]
EVANS BLUE Drug Info [4]
Gadofosveset Drug Info [7]
Oxyphenbutazone Drug Info
RU-101 Drug Info [15]
Binder Bismuth Drug Info [16]
Ebselen Drug Info [17]
Gadobenate Dimeglumine Drug Info [18]
Iodipamide Drug Info [19]
Sodium lauryl sulfate Drug Info [20]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
Reactome Platelet degranulation
Recycling of bile acids and salts
HDL-mediated lipid transport
Scavenging of heme from plasma
WikiPathways Human Complement System
Binding and Uptake of Ligands by Scavenger Receptors
Lipid digestion, mobilization, and transport
Transport of vitamins, nucleosides, and related molecules
Bile acid and bile salt metabolism
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
REF 1Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 2The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology. 1991 Oct;101(4):889-94.
REF 3Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112.
REF 4The ChEMBL database in 2017.
REF 52004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
REF 6FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021357.
REF 72008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF 8FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009321.
REF 9(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7400).
REF 10Drug information of Sodium lauryl sulfate, 2008. eduDrugs.
REF 11ClinicalTrials.gov (NCT02484638) Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors.
REF 12ClinicalTrials.gov (NCT01843894) A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye. U.S. National Institutes of Health.
REF 13ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
REF 14Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 15Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283.
REF 16Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. Epub 2000 Dec 7.
REF 17Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
REF 18Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
REF 19Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. Epub 2008 Mar 21.
REF 20Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.